Neonatal necrotizing enterocolitis -inflammation and intestinal immaturity

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2009, Pages 248-259

  Claud, Erika C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Human milk; Neonatal necrotizing enterocolitis; Nuclear factor kappaB; Platelet activating factor; Premature infant; Probiotic

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ABC DOPHILUS; ANTIINFLAMMATORY AGENT; INFLORAN; NEMO BINDING DOMAIN PROTEIN; PENTOXIFYLLINE; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BREAST MILK; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE COURSE; DISEASE PREDISPOSITION; ENTERITIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE EPITHELIUM; INTESTINE FLORA; NECROTIZING ENTEROCOLITIS; NONHUMAN; PERMEABILITY BARRIER; PREMATURITY; REVIEW; RISK FACTOR; SYMPTOMATOLOGY;

EID: 73549100466     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309789152020     Document Type: Review

References (146)

1. Martin J.A.; Kung H.C.; Mathews T.J.; Hoyert D.L.; Strobino D.M.; Guyer B.; Sutton S.R. Annual summary of vital statistics: 2006. Pediatrics, 2008, 121(4), 788-801.
2. Van Marter L.J.; Dammann O.; Allred E.N.; Leviton A.; Pagano M.; Moore M.; Martin C. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J. Pediatr., 2002, 140(2), 171-176.
3. Blahnik M.J.; Ramanathan R.; Riley C.R.; Minoo P. Lipopolysaccharide- induced tumor necrosis factor-alpha and IL-10 production by lung macrophages from preterm and term neonates. Pediatr. Res., 2001, 50(6), 726-731.
4. Chheda S.; Palkowetz K.H.; Garofalo R.; Rassin D.K.; Goldman A.S. Decreased interleukin-10 production by neonatal monocytes and T cells: relationship to decreased production and expression of tumor necrosis factor-alpha and its receptors. Pediatr. Res., 1996, 40(3), 475-483.
5. Jones C.A.; Cayabyab R.G.; Kwong K.Y.; Stotts C.; Wong B.; Hamdan H.; Minoo P.; deLemos R.A. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr. Res., 1996, 39(6), 966-975.
6. Kosloske A.M. Epidemiology of necrotizing enterocolitis. Acta Paediatr. Suppl., 1994, 396, 2-7.
7. MacKendrick W.; Caplan M. Necrotizing enterocolitis. New thoughts about pathogenesis and potential treatments. Pediatr. Clin. North Am.,1993, 40(5), 1047-1059.
8. Rayyis S.F.; Ambalavanan N.; Wright L.; Carlo W.A. Randomized trial of "slow"; versus "fast"; feed advancements on the incidence of necrotizing enterocolitis in very low birth weight infants. J. Pediatr., 1999, 134(3), 293-297.
9. Fitzgibbons S.C.; Ching Y.; Yu D.; Carpenter J.; Kenny M.; Weldon C.; Lillehei C.; Valim C.; Horbar J.D.; Jaksic T. Mortality of necrotizing enterocolitis expressed by birth weight categories. J. Pediatr. Surg., 2009, 44(6), 1072-1075; discussion 1075-1076.
10. Ballance W.A.; Dahms B.B.; Shenker N.; Kliegman R.M. Pathology of neonatal necrotizing enterocolitis: a ten-year experience. J. Pediatr., 1990, 117(1 Pt 2), S6-13.
11. Faix R.G.; Adams J.T. Neonatal necrotizing enterocolitis: current concepts and controversies. Adv. Pediatr. Infect. Dis., 1994, 9, 1-36.
12. Hintz S.R.; Kendrick D.E.; Stoll B.J.; Vohr B.R.; Fanaroff A.A.; Donovan E.F.; Poole W.K.; Blakely M.L.; Wright L.; Higgins R. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics, 2005, 115(3), 696-703.
13. Claud E.C.; Walker W.A. Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. FASEB J., 2001, 15(8), 1398-1403.
14. Eckburg P.B.; Bik E.M.; Bernstein C.N.; Purdom E.; Dethlefsen L.; Sargent M.; Gill S.R.; Nelson K.E.; Relman D.A. Diversity of the human intestinal microbial flora. Science, 2005, 308(5728), 1635-1638.
15. Relman D.A. The search for unrecognized pathogens. Science, 1999, 284(5418), 1308-1310.
16. Wang Y., Hoenig J.D.; Malin K.J.; Qamar S.; Petrof E.O.; Sun J.; Antonopoulos D.A.; Chang E.B.; Claud E.C. 16S rRNA genebased analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J., 2009.
17. Berseth C.L. Gestational evolution of small intestine motility in preterm and term infants. J. Pediatr., 1989, 115(4), 646-651.
18. Berseth C.L. Neonatal small intestinal motility: motor responses to feeding in term and preterm infants. J. Pediatr., 1990, 117(5), 777-782.
19. Berseth C.L. Gut motility and the pathogenesis of necrotizing enterocolitis. Clin. Perinatol., 1994, 21(2), 263-270.
20. Chu S.H.; Walker W.A. Developmental changes in the activities of sialyl- and fucosyltransferases in rat small intestine. Biochim. Biophys. Acta, 1986, 883(3), 496-500.
21. Dai D.; Nanthakumar N.N.; Savidge T.C.; Newburg D.S.; Walker W.A. Region-specific ontogeny of alpha-2,6-sialyltransferase during normal and cortisone-induced maturation in mouse intestine. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 282(3), G480-490.
22. Dai D.; Nanthkumar N.N.; Newburg D.S.; Walker W.A. Role of oligosaccharides and glycoconjugates in intestinal host defense. J. Pediatr. Gastroenterol. Nutr., 2000, 30(Suppl 2), S23-33.
23. Snyder J.D.; Walker W.A. Structure and function of intestinal mucin: developmental aspects. Int. Arch. Allergy Appl. Immunol., 1987, 82(3-4), 351-356.
24. Udall J.N., Jr. Gastrointestinal host defense and necrotizing enterocolitis. J. Pediatr., 1990, 117(1 Pt 2), S33-43.
25. Eibl M.M.; Wolf H.M.; Furnkranz H.; Rosenkranz A.: Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N. Engl. J. Med., 1988, 319(1), 1-7.
26. Roberts S.A.; Freed D.L. Neonatal IgA secretion enhanced by breast feeding. Lancet, 1977, 2(8048), 1131.
27. Tan X.D.; Hsueh W.; Chang H.; Wei K.R.; Gonzalez-Crussi F. Characterization of a putative receptor for intestinal trefoil factor in rat small intestine: identification by in situ binding and ligand blotting. Biochem. Biophys. Res. Commun., 1997, 237(3), 673-677.
28. Sands B.E.; Podolsky D.K. The trefoil peptide family. Annu. Rev. Physiol., 1996, 58, 253-273.
29. Lin J.; Holzman I.R.; Jiang P.; Babyatsky M.W. Expression of intestinal trefoil factor in developing rat intestine. Biol. Neonate., 1999, 76(2), 92-97.
30. Ouellette A.J. Paneth cells and innate immunity in the crypt micro-environment. Gastroenterology, 1997, 113(5), 1779-1784.
31. Salzman N.H.; Polin R.A.; Harris M.C.; Ruchelli E.; Hebra A.; Zirin-Butler S.; Jawad A.; Martin Porter E.; Bevins C.L. Enteric defensin expression in necrotizing enterocolitis. Pediatr. Res., 1998, 44(1), 20-26.
32. Rouwet E.V.; Heineman E.; Buurman W.A.; ter Riet G.; Ramsay G.; Blanco C.E. Intestinal permeability and carrier-mediated monosaccharide absorption in preterm neonates during the early postnatal period. Pediatr. Res., 2002, 51(1), 64-70.
33. Claud E.C.; Lu L.; Anton P.M.; Savidge T.; Walker W.A.; Cherayil B.J. Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. Proc. Natl. Acad. Sci. USA, 2004, 101(19), 7404-7408.
34. Nusrat A.; Turner JR.; Madara J.L. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am. J. Physiol. Gastrointest. Liver. Physiol., 2000, 279(5): G851-857.
35. Clark J.A.; Doelle S.M.; Halpern M.D.; Saunders T.A.; Holubec H.; Dvorak K.; Boitano S.A.; Dvorak B. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 291(5), G938-949.
36. Metcalfe A.; Streuli C. Epithelial apoptosis. Bioessays, 1997, 19(8), 711-720.
37. McConkey D.J.; Orrenius S. Signal transduction pathways in apoptosis. Stem Cells, 1996, 14(6), 619-631.
38. Torriglia A.; Perani P.; Brossas J.Y.; Altairac S.; Zeggai S.; Martin E.; Treton J.; Courtois Y.; Counis M.F. A caspase-independent cell clearance program. The LEI/L-DNase II pathway. Ann. NY Acad. Sci., 2000, 926, 192-203.
39. Jilling T.; Lu J.; Jackson M.; Caplan M.S. Intestinal epithelial apoptosis initiates gross bowel necrosis in an experimental rat model of neonatal necrotizing enterocolitis. Pediatr. Res., 2004, 55(4), 622-629.
40. Budihardjo I.; Oliver H.; Lutter M.; Luo X.; Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 1999, 15, 269-290.
41. Lane J.S.; Todd K.E.; Lewis M.P.; Gloor B.; Ashley S.W.; Reber H.A.; McFadden D.W; Chandler C.F. Interleukin-10 reduces the systemic inflammatory response in a murine model of intestinal ischemia/reperfusion. Surgery, 1997, 122(2), 288-294.
42. Barry M.A.; Eastman A. Endonuclease activation during apoptosis: the role of cytosolic Ca2+ and pH. Biochem. Biophys. Res. Commun., 1992, 186(2), 782-789.
43. Park H.J.; Lyons J.C.; Ohtsubo T.; Song C.W. Acidic environment causes apoptosis by increasing caspase activity. Br. J. Cancer, 1999, 80(12), 1892-1897.
44. Rachmilewitz D.; Eliakim R.; Simon P.; Ligumsky M.; Karmeli F. Cytokines and platelet-activating factor in human inflamed colonic mucosa. Agents Actions, 1992, Spec No: C32-36.
45. Sobhani I.; Hochlaf S.; Denizot Y.; Vissuzaine C.; Rene E.; Benveniste J.; Lewin M.M.; Mignon M. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut, 1992, 33(9), 1220-1225.
46. Denizot Y.; Chaussade S.; Nathan N.; Colombel J.F.; Bossant M.J.; Cherouki N.; Benveniste J.; Couturier D. PAF-acether and acetylhydrolase in stool of patients with Crohn's disease. Dig. Dis. Sci., 1992, 37(3), 432-437.
47. Kald B.; Smedh K.; Olaison G.; Sjodahl R.; Tagesson C. Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn's disease. Digestion, 1996, 57(6), 472-477.
48. Caplan M.S.; Hedlund E.; Adler L.; Lickerman M.; Hsueh W. The platelet-activating factor receptor antagonist WEB 2170 prevents neonatal necrotizing enterocolitis in rats. J. Pediatr. Gastroenterol. Nutr., 1997, 24(3), 296-301.
49. Rabinowitz S.S.; Dzakpasu P.; Piecuch S.; Leblanc P.; Valencia G.; Kornecki E. Platelet-activating factor in infants at risk for necrotizing enterocolitis. J. Pediatr., 2001, 138(1), 81-86.
50. Amer M.D.; Hedlund E.; Rochester J.; Caplan M.S. Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis. Biol. Neonate., 2004, 85(3), 159-166.
51. Caplan M.S.; Sun X.M.; Hseuh W.; Hageman J.R. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J. Pediatr., 1990, 116(6), 960-964.
52. Hwang S. Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. J. Lipid. Mediat., 1990, 2(3-4), 123-158.
53. Hsueh W.; Gonzalez-Crussi F. Ischemic bowel necrosis induced by platelet-activating factor: an experimental model. Methods Achiev. Exp. Pathol., 1988, 13, 208-239.
54. Caplan M.S.; Kelly A.; Hsueh W. Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor. Pediatr. Res., 1992, 31(5), 428-434.
55. Hsueh W.; Gonzalez-Crussi F.; Arroyave J.L.; Anderson R.C.; Lee M.L.; Houlihan W.J. Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists. Eur. J. Pharmacol., 1986, 123(1), 79-83.
56. Wallace J.L.; Steel G.; Whittle B.J.; Lagente V.; Vargaftig B. Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat:effects of three platelet-activating factor antagonists. Gastroenterology, 1987, 93(4), 765-773.
57. Lu J.; Caplan M.S.; Saraf A.P.; Li D.; Adler L.; Liu X.; Jilling T. Platelet-activating factor-induced apoptosis is blocked by Bcl-2 in rat intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286(2), G340-350.
58. Lu J.; Caplan M.S.; Li D.; Jilling T. Polyunsaturated fatty acids block platelet-activating factor-induced phosphatidylinositol 3 kinase/Akt-mediated apoptosis in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294(5), G1181-1190.
59. Claud E.C.; Lu J.; Wang X.Q.; Abe M.; Petrof E.O.; Sun J.; Nelson D.J.; Marks J.; Jilling T. Platelet-activating factor-induced chloride channel activation is associated with intracellular acidosis and apoptosis of intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294(5), G1191-1200.
60. Ford H.; Watkins S.; Reblock K.; Rowe M. The role of inflammatory cytokines and nitric oxide in the pathogenesis of necrotizing enterocolitis. J. Pediatr. Surg., 1997, 32(2), 275-282.
61. Zamora R.; Grishin A.; Wong C.; Boyle P.; Wang J.; Hackam D.; Upperman J.S.; Tracey K.J.; Ford H.R. High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289(4), G643-652.
62. Baggiolini M.; Walz A.; Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest., 1989, 84(4), 1045-1049.
63. Djeu J.Y.; Matsushima K.; Oppenheim J.J.; Shiotsuki K.; Blanchard D.K. Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. J. Immunol., 1990, 144(6), 2205-2210.
64. Huber A.R.; Kunkel S.L.; Todd R.F. 3rd; Weiss S.J. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science, 1991, 254(5028), 99-102.
65. Edelson M.B.; Bagwell C.E.; Rozycki H.J. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics, 1999, 103(4 Pt 1),766-771.
66. Nadler E.P.; Stanford A.; Zhang X.R.; Schall L.C.; Alber S.M; Watkins S.C.; Ford H.R. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease. J. Pediatr. Surg., 2001, 36(8), 1122-1129.
67. Morecroft J.A.; Spitz L.; Hamilton P.A.; Holmes S.J. Plasma cytokine levels in necrotizing enterocolitis. Acta Paediatr. Suppl., 1994, 396, 18-20.
68. Morecroft J.A.; Spitz L.; Hamilton P.A.; Holmes S.J. Plasma interleukin-6 and tumour necrosis factor levels as predictors of disease severity and outcome in necrotizing enterocolitis. J. Pediatr. Surg., 1994, 29(6), 798-800.
69. Claud E.C.; Savidge T.; Walker W.A. Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. Pediatr. Res., 2003, 53(3), 419-425.
70. Nanthakumar N.N.; Fusunyan R.D.; Sanderson I.; Walker W.A. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. Proc. Natl. Acad. Sci. USA, 2000, 97(11), 6043-6048.
71. Jilling T.; Simon D.; Lu .; Meng F.J.; Li D.; Schy R.; Thomson R.B.; Soliman A.; Arditi M.; Caplan M.S. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J. Immunol., 2006, 177(5), 3273-3282.
72. Ghosh S.; Karin M. Missing pieces in the NF-kappaB puzzle. Cell, 2002, 109 (Suppl), S81-96.
73. DiDonato J.A.; Hayakawa M.; Rothwarf D.M.; Zandi E.; Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature, 1997, 388(6642), 548-554.
74. Roff M.; Thompson J.; Rodriguez M.S.; Jacque J.M.; Baleux F.; Arenzana-Seisdedos F.; Hay R.T. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J. Biol. Chem., 1996, 271(13), 7844-7850.
75. Chiao P.J.; Miyamoto S.; Verma I.M. Autoregulation of I kappa B alpha activity. Proc. Natl. Acad. Sci. USA, 1994, 91(1), 28-32.
76. Sun S.C.; Ganchi P.A.; Ballard D.W.; Greene W.C. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science, 1993, 259(5103), 1912-1915.
77. Claud E.C.; Zhang X.; Petrof E.O.; Sun J. Developmentally regulated tumor necrosis factor-alpha induced nuclear factor-kappaB activation in intestinal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292(5), G1411-1419.
78. Kassinen A.; Krogius-Kurikka L.; Makivuokko H.; Rinttila T.; Paulin L.; Corander J.; Malinen E.; Apajalahti J.; Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology, 2007, 133(1), 24-33.
79. Baregamian N.; Mourot J.M.; Ballard A.R.; Evers B.M.; Chung D.H. PPAR-gamma agonist protects against intestinal injury during necrotizing enterocolitis. Biochem. Biophys. Res. Commun., 2009, 379(2), 423-427.
80. De Plaen I.G.; Liu S.X.; Tian R.; Neequaye I.; May M.J.; Han X.B.; Hsueh W.; Jilling T.; Lu J.; Caplan M.S. Inhibition of nuclear factor-kappaB ameliorates bowel injury and prolongs survival in a neonatal rat model of necrotizing enterocolitis. Pediatr. Res., 2007, 61(6), 716-721.
81. Shibolet O.; Podolsky D.K. TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292(6), G1469-1473.
82. Kelly D.; Campbell J.I.; King T.P.; Grant G.; Jansson E.A.; Coutts A.G.; Pettersson S.; Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol., 2004, 5(1), 104-112.
83. Travadi J.; Patole S.; Charles A.; Dvorak B.; Doherty D.; Simmer K.: Pentoxifylline reduces the incidence and severity of necrotizing enterocolitis in a neonatal rat model. Pediatr. Res., 2006, 60(2), 185-189.
84. Lucas A.; Cole T.J. Breast milk and neonatal necrotising enterocolitis. Lancet, 1990, 336(8730), 1519-1523.
85. Meinzen-Derr J.; Poindexter B.; Wrage L.; Morrow A.L.; Stoll B.; Donovan E.F. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. J. Perinatol., 2009, 29(1), 57-62.
86. Wagner C.L. Amniotic fluid and human milk: a continuum of effect? J. Pediatr. Gastroenterol. Nutr., 2002, 34(5), 513-514.
87. Lawrence G.; Bates J.; Gaul A.: Pathogenesis of neonatal necrotising enterocolitis. Lancet, 1982, 1(8264), 137-139.
88. Arvola T.; Laiho K.; Torkkeli S.; Mykkanen H.; Salminen S.; Maunula L.; Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics, 1999, 104(5), e64.
89. Gionchetti P.; Rizzello F.; Venturi A.; Brigidi P.; Matteuzzi D.; Bazzocchi G.; Poggioli G.; Miglioli M.; Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 2000, 119(2), 305-309.
90. Gionchetti P.; Rizzello F.;, Venturi A.; Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J. Gastroenterol. Hepatol., 2000, 15(5), 489-493.
91. Surawicz C.M. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract. Res. Clin. Gastroenterol., 2003, 17(5), 775-783.
92. Hoyos A.B.: Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int. J. Infect. Dis., 1999, 3(4), 197-202.
93. Lin H.C.; Su B.H.; Chen A.C.; Lin T.W.; Tsai C.H.; Yeh T.F.; Oh W. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics, 2005, 115(1), 1-4.
94. Lin H.C.; Hsu C.H.; Chen H.L.; Chung M.Y.; Hsu J.F.; Lien R.I.; Tsao L.Y.; Chen C.H.; Su B.H. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics, 2008, 122(4), 693-700.
95. Bin-Nun A.; Bromiker R.; Wilschanski M.;. Kaplan M.; Rudensky B.; Caplan M.; Hammerman C. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J. Pediatr., 2005, 147(2), 192-196.
96. Harmsen H.J.; Wildeboer-Veloo A.C.; Raangs G.C.; Wagendorp A.A.; Klijn N.; Bindels J.G.; Welling G.W. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J. Pediatr. Gastroenterol. Nutr., 2000, 30(1), 61-67.
97. Gewolb I.H.; Schwalbe R.S.; Taciak V.L.; Harrison T.S.; Panigrahi P. Stool microflora in extremely low birthweight infants. Arch. Dis. Child Fetal Neonatal. Ed., 1999, 80(3), F167-173.
98. Rubaltelli F.F.; Biadaioli R.; Pecile P.; Nicoletti P. Intestinal flora in breast- and bottle-fed infants. J. Perinat. Med., 1998, 26(3), 186-191.
99. Tomkins A.M.; Bradley A.K.; Oswald S.; Drasar B.S. Diet and the faecal microflora of infants, children and adults in rural Nigeria and urban U.K. J .Hyg. (Lond)., 1981, 86(3), 285-293.
100. Wold A.E.; Adlerberth I. Breast feeding and the intestinal microflora of the infant--implications for protection against infectious diseases. Adv. Exp. Med. Biol., 2000, 478, 77-93.
101. Morrow A.L.; Ruiz-Palacios G.M.; Jiang X.; Newburg D.S. Human-milk glycans that inhibit pathogen binding protect breastfeeding infants against infectious diarrhea. J. Nutr., 2005, 135(5), 1304-1307.
102. Newburg D.S. Oligosaccharides in human milk and bacterial colonization. J. Pediatr. Gastroenterol. Nutr., 2000, 30(Suppl 2), S8-17.
103. Goldman A.S.; Garza C.; Nichols B.L.; Goldblum R.M. Immunologic factors in human milk during the first year of lactation. J. Pediatr., 1982, 100(4), 563-567.
104. Goldman A.S.; Goldblum R.M.; Hanson L.A. Anti-inflammatory systems in human milk. Adv. Exp. Med. Biol., 1990, 262, 69-76.
105. Coppa G.V.; Zampini L.; Galeazzi T.; Gabrielli O. Prebiotics in human milk: a review. Dig. Liver Dis., 2006, 38(Suppl 2), S291-294.
106. Christensen H.R.; Frokiaer H.; Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J. Immunol., 2002, 168(1), 171-178.
107. Yan F.; Polk D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem., 2002, 277(52), 50959-50965.
108. Hooper L.V.; Wong M.H.; Thelin A.; Hansson L.; Falk P.G.; Gordon J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science, 2001, 291(5505), 881-884.
109. Annuk H.; Shchepetova J.; Kullisaar T.; Songisepp E.; Zilmer M.; Mikelsaar M. Characterization of intestinal lactobacilli as putative probiotic candidates. J. Appl. Microbiol., 2003, 94(3), 403-412.
110. Braude A.I.; Siemienski J.S. The influence of bacteriocins on resistance to infection by gram-negative bacteria. II. Colicin action, transfer of colicinogeny, and transfer of antibiotic resistance in urinary infections. J. Clin. Invest., 1968, 47(8), 1763-1773.
111. Cleveland J.; Montville T.J.; Nes I.F.; Chikindas M.L. Bacteriocins: safe, natural antimicrobials for food preservation. Int. J. Food Microbiol., 2001, 71(1), 1-20.
112. Kullisaar T.; Zilmer M.; Mikelsaar M.; Vihalemm T.; Annuk H.; Kairane C.; Kilk A. Two antioxidative lactobacilli strains as promising probiotics. Int. J. Food Microbiol., 2002, 72(3), 215-224.
113. Ocana V.S.; Pesce de Ruiz Holgado A.A.; Nader-Macias M.E. Selection of vaginal H2O2-generating Lactobacillus species for probiotic use. Curr. Microbiol., 1999, 38(5), 279-284.
114. Paraje M.G.; Albesa I.; Eraso A.J. Conservation in probiotic preparations of Lactobacillus with inhibitory capacity on other species. New Microbiol., 2000, 23(4), 423-431.
115. Sullivan P.B.; Lewindon P.J.; Cheng C.; Lenehan P.F.; Kuo B.S.; Haskins J.R.; Goodlad R.A.; Wright N.A.; de la Iglesia F.A. Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis. J. Pediatr. Surg., 2007, 42(3), 462-469.
116. Fagbemi A.O.; Wright N.; Lakhoo K.; Edwards A.D. Immunoreactive epidermal growth factor receptors are present in gastrointestinal epithelial cells of preterm infants with necrotising enterocolitis. Early Hum. Dev., 2001, 65(1):1-9.
117. Menard D.; Pothier P.: Radioautographic localization of epidermal growth factor receptors in human fetal gut. Gastroenterology, 1991, 101(3), 640-649.
118. Swaniker F.; Guo W.; Fonkalsrud E.W.; Diamond J. The effect of epidermal growth factor on mucosal function after ileal resection. J. Surg. Res., 1995, 58(6), 565-569.
119. Miettinen P.J.; Berger J.E.; Meneses J.; Phung Y.; Pedersen R.A.; Werb Z.; Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376(6538), 337-341.
120. Shin C.E.; Falcone R.A.; Jr., Stuart L.; Erwin C.R.; Warner B.W. Diminished epidermal growth factor levels in infants with necrotizing enterocolitis. J. Pediatr. Surg., 2000, 35(2), 173-176; discussion 177.
121. Dvorak B.; Halpern M.D.; Holubec H.; Williams C.S.; McWilliam D.L.; Dominguez J.A.; Stepankova R.; Payne C.M.; McCuskey R.S. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 282(1), G156-164.
122. Sullivan P.B.; Brueton M.J.; Tabara Z.B.; Goodlad R.A.; Lee C.Y.; Wright N.A. Epidermal growth factor in necrotising enteritis. Lancet, 1991, 338(8758), 53-54.
123. Feng J.; El-Assal O.N.; Besner G.E. Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. J. Pediatr. Surg., 2006, 41(1), 144-149; discussion 144-149.
124. Yu X.; Radulescu A.; Zorko N.; Besner G.E. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology, 2009, 137(1), 221-230.
125. Juul S.E.; Ledbetter D.J.; Joyce A.E.; Dame C.; Christensen R.D.; Zhao Y.; DeMarco V. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut, 2001, 49(2), 182-189.
126. Juul S.E.; Joyce A.E.; Zhao Y.; Ledbetter D.J. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr. Res., 1999, 46(3), 263-268.
127. Ledbetter D.J.; Juul S.E. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J. Pediatr. Surg., 2000, 35(2), 178-181; discussion 182.
128. Li N.; Lewis P.; Samuelson D.; Liboni K.; Neu J. Glutamine regulates Caco-2 cell tight junction proteins. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287(3): G726-733.
129. Otte J.M.; Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286(4), G613-626.
130. Resta-Lenert S.; Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut, 2003, 52(7), 988-997.
131. Garcia-Lafuente A.; Antolin M.; Guarner F.; Crespo E.; Malagelada J.R. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut, 2001, 48(4), 503-507.
132. Urao M.; Fujimoto T.; Lane G.J.; Seo G.; Miyano T. Does probiotics administration decrease serum endotoxin levels in infants? J. Pediatr. Surg., 1999, 34(2), 273-276.
133. Isolauri E.; Majamaa H.; Arvola T.; Rantala I.; Virtanen E.; Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology, 1993, 105(6), 1643-1650.
134. Mangell P.; Nejdfors P.; Wang M.; Ahrne S.; Westrom B.; Thorlacius H.; Jeppsson B. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig. Dis. Sci., 2002, 47(3), 511-516.
135. Moya F.R.; Eguchi H.; Zhao B.; Furukawa M.; Sfeir J.; Osorio M.; Ogawa Y.; Johnston J.M. Platelet-activating factor acetylhydrolase in term and preterm human milk: a preliminary report. J. Pediatr. Gastroenterol. Nutr., 1994, 19(2), 236-239.
136. Petrof E.O.; Kojima K.; Ropeleski M.J.; Musch M.W.; Tao Y.; De Simone C.; Chang E.B. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology, 2004, 127(5), 1474-1487.
137. Lammers K.M.; Helwig U.; Swennen E.; Rizzello F.; Venturi A.; Caramelli E.; Kamm M.A.; Brigidi P.; Gionchetti P.; Campieri M. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am. J. Gastroenterol., 2002, 97(5), 1182-1186.
138. Jijon H.; Backer J.; Diaz H.; Yeung H.; Thiel D.; McKaigney C.; De Simone C.; Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology, 2004, 126(5), 1358-1373.
139. Antony S.J. Lactobacillemia: an emerging cause of infection in both the immunocompromised and the immunocompetent host. J. Natl. Med. Assoc., 2000, 92(2), 83-86.
140. Horwitch C.A.; Furseth H.A.; Larson A.M.; Jones T.L.; Olliffe J.F.; Spach D.H. Lactobacillemia in three patients with AIDS. Clin. Infect. Dis., 1995, 21(6), 1460-1462.
141. Schlegel L.; Lemerle S.; Geslin P. Lactobacillus species as opportunistic pathogens in immunocompromised patients. Eur. J. Clin. Microbiol. Infect. Dis., 1998, 17(12), 887-888.
142. De Groote M.A.; Frank D.N.; Dowell E.; Glode M.P.; Pace N.R. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr. Infect. Dis. J., 2005, 24(3), 278-280.
143. Wagner R.D.; Warner T.; Roberts L.; Farmer J.; Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect. Immun., 1997, 65(8), 3345-3351.
144. Petrof E.O.; Claud E.C.; Sun J.; Abramova T.; Guo Y.; Waypa T.S.; He S.M.; Nakagawa Y.; Chang E.B. Bacteria-free solution derived from lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function. Inflamm. Bowel. Dis., 2009.
145. Gribar S.C.; Sodhi C.P.; Richardson W.M.; Anand R.J.; Gittes G.K.; Branca M.F.; Jakub A.; Shi X.H.; Shah S.; Ozolek J.A.; Hackam D.A. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J. Immunol., 2009, 182(1), 636-646.
146. th ed; Walker, G., Kleinman, S., Shneider, S., Eds.; BC Decker: Canada 2004; pp. 871-879.